menu
    • menu
    [{"orgOrder":0,"company":"CuradhMTR","sponsor":"Alpha Fusion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2025","type":"Partnership","leadProduct":"af-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CuradhMTR","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuradhMTR \/ CuradhMTR","highestDevelopmentStatusID":"6","companyTruncated":"CuradhMTR \/ CuradhMTR"},{"orgOrder":0,"company":"CuradhMTR","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CuradhMTR","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuradhMTR \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"CuradhMTR \/ NorthStar Medical Radioisotopes"}]

    Find Clinical Drug Pipeline Developments & Deals by CuradhMTR

    Menu

    CuradhMTR

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CuradhMTR

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            CuradhMTR

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : af-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Alpha Fusion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alpha Fusion and Curadh Enter into Partnership to Advance At-211 Radiopharmaceuticals

                            Details : The collaboration combines Alpha Fusion's leading role in At-211 drug discovery of af-001 and early clinical work in Japan, with Curadh's global expertise in radiopharmaceutical development.

                            Product Name : af-001

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : af-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Alpha Fusion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CuradhMTR

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            CuradhMTR

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NorthStar, Curadh Enter Agreement for Actinium-225-Based Radiopharmaceuticals

                            Details : NorthStar will use its technology and expertise to develop selected Curadh radiopharmaceutical targets for solid tumor cancer diagnosis and treatment.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth